Geron Co. (GERN) Given Consensus Rating of “Hold” by Analysts
Geron Co. (NASDAQ:GERN) has received an average rating of “Hold” from the six brokerages that are covering the company, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and two have given a buy rating to the company. The average 1 year target price among analysts that have covered the stock in the last year is $3.75.
Several research firms have recently weighed in on GERN. BidaskClub upgraded shares of Geron from a “strong sell” rating to a “sell” rating in a research note on Thursday, January 11th. Zacks Investment Research downgraded shares of Geron from a “buy” rating to a “hold” rating in a research note on Tuesday, October 10th. Stifel Nicolaus reiterated a “hold” rating and issued a $2.50 target price on shares of Geron in a research note on Friday, November 3rd. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of Geron in a research note on Friday, November 3rd.
Geron (NASDAQ:GERN) opened at $2.04 on Tuesday. The firm has a market cap of $324.83, a PE ratio of -11.33 and a beta of 2.59. Geron has a 12 month low of $1.74 and a 12 month high of $3.15.
A number of large investors have recently modified their holdings of the stock. Russell Investments Group Ltd. grew its stake in Geron by 783.9% during the third quarter. Russell Investments Group Ltd. now owns 363,990 shares of the biopharmaceutical company’s stock valued at $794,000 after acquiring an additional 322,810 shares in the last quarter. Raymond James Financial Services Advisors Inc. grew its stake in Geron by 42.0% during the third quarter. Raymond James Financial Services Advisors Inc. now owns 82,426 shares of the biopharmaceutical company’s stock valued at $180,000 after acquiring an additional 24,370 shares in the last quarter. IHT Wealth Management LLC purchased a new position in Geron during the second quarter valued at approximately $122,000. State Street Corp grew its stake in Geron by 9.8% during the second quarter. State Street Corp now owns 5,127,578 shares of the biopharmaceutical company’s stock valued at $14,205,000 after acquiring an additional 459,700 shares in the last quarter. Finally, Zacks Investment Management purchased a new position in Geron during the second quarter valued at approximately $148,000. 39.21% of the stock is owned by institutional investors.
COPYRIGHT VIOLATION WARNING: “Geron Co. (GERN) Given Consensus Rating of “Hold” by Analysts” was first posted by American Banking News and is the sole property of of American Banking News. If you are viewing this article on another site, it was copied illegally and reposted in violation of United States & international trademark and copyright law. The correct version of this article can be read at https://www.americanbankingnews.com/2018/01/16/geron-co-gern-given-consensus-rating-of-hold-by-analysts.html.
Geron Corporation (Geron) is a biopharmaceutical company, which supports the clinical stage development of a telomerase inhibitor, Imetelstat, in hematologic myeloid malignancies by Janssen Biotech, Inc (Janssen). The Company is engaged in the development of therapeutic products for oncology. Using its nucleic acid chemistry, Geron designed Imetelstat to be an oligonucleotide that binds with high affinity to the ribonucleic acid (RNA) template of telomerase, thereby directly inhibiting telomerase activity.
Receive News & Ratings for Geron Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Geron and related companies with MarketBeat.com's FREE daily email newsletter.